StemRIM Inc. announced the commencement of a global late Phase 2 clinical trial of Redasemtide in patients with acute ischemic stroke in the United States. This developmental milestone was achieved after receiving approval from FDA, in response to a clinical trial plan submitted by Shionogi & Co. Ltd. on March 29, 2023.

Originally, a global Phase 3 trial was planned, but, for the purpose of dose setting, a global late Phase 2 trial was chosen instead. For further details, please refer to the disclosure made by Shionogi on April 10, 2023, titled "Initiation of a Global Late Phase 2 Clinical Trial of the Regeneration-Inducing MedicineTM Redasemtide in Patients with Acute Ischemic Stroke" for details. The trial is currently underway in Japan and the United States and is expected to start sequentially in Europe and China.